MCM
ARRY

Moore Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Moore Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-100,000
Closed -$1.23M – 322
2017
Q3 		$1.23M Buy
+100,000
New +$929K 0.02% 182

Other funds holding ARRY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Moore Capital Management's ARRY Position: Q4 2017 in Review

Moore Capital Management sold out of Array Biopharma Inc (ARRY) in Q4 2017, closing a stake of 100,000 shares — an estimated $1.23M sold.

Moore Capital Management first reported a position in ARRY in Q3 2017 and held it in 1 quarter. The position peaked at $1.23M in Q3 2017. 191 funds tracked by Wall St. Rank hold ARRY as of Q4 2017.

  • Moore Capital Management reported no remaining Array Biopharma Inc position as of Q4 2017 after selling out during the quarter.
  • Moore Capital Management sold 100,000 Array Biopharma Inc shares in Q4 2017, an estimated $1.23M.
  • Moore Capital Management first reported a position in Array Biopharma Inc in Q3 2017 and held it in 1 quarter.
  • Moore Capital Management's Array Biopharma Inc position peaked at $1.23M in Q3 2017.
  • 191 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q4 2017.

Based on Moore Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.